Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. Until today this year the stock’s price performance recorded an increase of 45.52%. However, over the last six months, the performance has been weaker by 13.56%. The price of DNA increased 39.82% over the last 30 days. And in the last five days, it has surged by 16.37%.
The market performance of Ginkgo Bioworks Holdings Inc has been somewhat unstable. Over the past year, the company’s stock achieved a high of $64.40 on 02/29/24, with the lowest value for the same timeframe being $5.26, recorded on 09/10/24.
52-week price history of DNA Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Ginkgo Bioworks Holdings Inc’s current trading price is -77.81% away from its 52-week high, while its distance from the 52-week low is 171.67%. The stock’s price range over this timeframe has been between $5.26 and $64.40. The shares of the Healthcare sector company recorded a trading volume of approximately 1.5 million for the day, which was comparatively higher than the average daily volume of 1.39 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Ginkgo Bioworks Holdings Inc (DNA) has experienced a quarterly rise of 87.53% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 821.37M and boasts a workforce of 1218 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 9.06, with a change in price of +8.41. Similarly, Ginkgo Bioworks Holdings Inc recorded 1,325,909 in trading volume during the last 100 days, posting a change of +143.03%.
DNA’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for DNA stands at 0.56. Similarly, the long-term debt-to-equity ratio is also 0.56.
DNA Stock Stochastic Average
Ginkgo Bioworks Holdings Inc’s raw stochastic average for the past 50 days is currently at 96.19%. This represents a surge from the raw stochastic average of the last 20 days, which was recorded at 94.81%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 82.01% and 80.56%, respectively.
